Form 4 for LRMR Larimar Therapeutics, Inc.
Accepted 2026-03-02 00:00:00 ET · period of report 2026-02-27 · accession 0001193125-26-085515 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-02 | 2026-02-27 | LRMR | Hamilton Thomas Edward | Dir | P - Purchase | $5.00 | +100.0K | 664.8K | +18% | +$500.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-27 | P | A | 100,000 | $5.00 | 664,798 | D | — | — | (F1) Represents shares of common stock purchased in the underwritten offering of Larimar Therapeutics, Inc. at the offering price, which closed on February 27, 2026. |